Ezz Life Science Holdings Ltd. · ASX:EZZ
Ezz Life Science — FY2022 Earnings Presentation
23 slides from Ezz Life Science's earnings presentation, Oct 13, 2022
Slide 1: FY22 Results Presentation
al use only FY22 Results Presentation 13 October 2022
Slide 2: Disclaimer
DISCLAIMER This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below. This document is not a prospectus, product di
Slide 3: Agenda
AGENDA Section Topic Presenter Page al use only 1 Executive summary Mark Qin, Interim CEO, COO and co-founder 01 – 02 2 Company overview Mark Qin, Interim CEO, COO and co-founder 03 – 07 3 Financial information Anthony Guarna, CFO 08 – 12 4 Strategy and outlook Anthony Guarna, CFO 13 – 14
Slide 4: 1. Executive Summary
1. EXECUTIVE SUMMARY Mark Qin, Interim CEO, COO and co-founder, EZZ Life Science Holdings Limited al use only Section Topic Page 1.1 Financial overview 01 c 1.2 Operational overview 02
Slide 5: 1.1 Financial Overview
1.1 FINANCIAL OVERVIEW Revenue EBITDA NPAT EPS $15.0M $1.8M $1.3M 3.1c al use only Down by 32.6% from FY21 Down by 34.7% from FY21 Down by 35.4% from FY21 Down by 48.3% from FY21 Gross Margin Cash Conversion Ratio Debt to Equity Ratio Final dividend per share 50.0% 1.4 0.0% 0.45c Down from 55.9% in
Slide 6: 1.2 Operational Overview
1.2 OPERATIONAL OVERVIEW Research and Development Channel Diversification Marketing ROI Average Sites Traffic Growth 7 4 81.1% 30.7% al use only new products new channels /month under the EZZ brand added to e-commerce strategies Up from 53.2% in FY21 from Oct 2021 to Sep 2022 Revenue from Revenue fr
Slide 7: 2. Company Overview
2. COMPANY OVERVIEW Mark Qin, Interim CEO, COO and co-founder, EZZ Life Science Holdings Limited al use only Section Topic Page 2.1 Who we are 03 2.2 What we do 04 c 2.3 Our history 05 2.4 Why we are different 06 2.5 Share information 07
Slide 8: 2.1 Who We Are
2.1 WHO WE ARE Vision, Mission and Values Value Creating Strategies Delivering Return to Shareholders Vision 1 Strengthen existing operations through performance excellence Employ strong management teams to drive long-term earnings growth, and al use only Improve quality of life and human health dep
Slide 9: 2.2 What We Do
2.2 WHAT WE DO We formulate, produce and market health and wellbeing products under We are an exclusive wholesale distributor of EAORON branded skin care the brand of EZZ, with a focus on products with significant demand from products in Australia and New Zealand to pharmacies, supermarkets and al u
Slide 10: 2.3 Our History
2.3 OUR HISTORY Started operations as a Commenced development, Became an exclusive Listed on the Australian Continue to execute Five- wholesale distributor of production and marketing distributor of the Securities Exchange Year Strategic Plan and the EAORON branded of the EZZ branded health EAORON b
Slide 11: 2.4 Why We Are Different
2.4 WHY WE ARE DIFFERENT Demand Driven Research and Development + Strong Marketing Capabilities Chemists Specialist Retailers Grocery Retailers Supermarkets E-commerce al use only 600+ 130+ 200+ 7,500+ 750+ #1 among the best selling nutrition and #1 among The best selling children’s #1 among the hig
Slide 12: 2.5 Share Information
2.5 SHARE INFORMATION Share Price Movements Share Information ASX code: EZZ al use only Close on 11 October 2022 $0.305 Shares on Issue: 42.8M Market cap 11 October 2022: $13M 52-week price range: $0.27-$0.55 Top Five Shareholders Macquarie Holdings Pty Ltd 39.8% JNJ Mok Pty Ltd 26.5% Yong Cao 4.1%
Slide 13: 3. Financial Overview
3. FINANCIAL OVERVIEW Anthony Guarna, CFO, EZZ Life Science Holdings Limited al use only Section Topic Page 3.1 Revenue 08 3.2 Margins 09 3.3 Financial position 10 3.4 Working capital 11 3.5 Cash flows 12
Slide 14: 3.1 Revenue
3.1 REVENUE Revenue Drivers Revenue by Segment al use only 08
Slide 15: 3.2 Margins
3.2 MARGINS Gross Margin EBITDA Margin Net Margin al use only 09
Slide 16: 3.3 Financial Position
3.3 FINANCIAL POSITION al use only Equity Debt1 $11.4M $0 1 Excluding lease liabilities 10
Slide 17: 3.4 Working Capital
3.4 WORKING CAPITAL Working Capital Movements Cash Conversion Cycle al use only 11
Slide 18: 3.5 Cash Flows
3.5 CASH FLOWS Cash Flows Movements al use only 12
Slide 19: 4. Strategy and Outlook
4. STRATEGY AND OUTLOOK Mark Qin, Interim CEO, COO and co-founder, EZZ Life Science Holdings Limited al use only Section Topic Page 4.1 Strategic focus 13 4.2 Outlook 14 c
Slide 20: 4.1 Strategic Focus
4.1 STRATEGIC FOCUS Life Science Technology People Consumers Product development pipeline to Online store and data backed Ongoing investment in people Connection to consumers increasingly feature healthcare analytical capability to enable and talent to support growth through omni-channel strategies
Slide 21: 4.2 FY23 Outlook
4.2 FY23 OUTLOOK 10New + Invest in research and development to accelerate innovation to the market with a focus on high margin and high demand products. products al use only Complement the bricks and mortar distribution points in Australia and New Zealand with digital strategies through EZZ and EAOR
Slide 22: Q&A
al use only Q&A
Slide 23: EZZ Life Science Holdings Limited
EZZ LIFE SCIENCE HOLDINGS LIMITED [ASX: EZZ] al use only EZZ Life Science Holdings Limited ABN 83 608 363 604 104 Derby Street, Silverwater NSW 2128 T: 02 9160 2305 E: ir@ezzlife.com.au EZZLifescience linkedin.com/company/ez EZZAustralia EZZ_Australia www.ezzlife.com.au z-life-science-holdings
EZZ Life Science Holdings — FY2022 Earnings Presentation on 6ix